Tumor microenvironment

Incendia Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research 2024

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Pharmaceutical, Health, Oncology, TME, Orientation, Workflow, Tissue, Neoplasm, Research, Tumor microenvironment, CRC, Colorectal cancer

An end-to-end 3D spatial biology workflow, Alpenglow’s 3D I/O Pro™, was applied to colorectal cancer (CRC) tissues stained with nuclear and general protein fluorescent dyes to quantify lymphocyte density in tumor parenchyma and stroma and analyze collagen features, including orientation, within 3D regions of interest in the TME.

Key Points: 
  • An end-to-end 3D spatial biology workflow, Alpenglow’s 3D I/O Pro™, was applied to colorectal cancer (CRC) tissues stained with nuclear and general protein fluorescent dyes to quantify lymphocyte density in tumor parenchyma and stroma and analyze collagen features, including orientation, within 3D regions of interest in the TME.
  • The ratio of stromal to parenchymal lymphocytes (lymphocyte infiltration ratio) varied from 1.4 up to 9.1 in 3D volumes and 1 to 25 in 2D virtual sections taken throughout all 5 CRC samples.
  • Qualitatively, areas with perpendicular collagen had more lymphocyte infiltration into the tumor parenchyma than areas with parallel collagen orientation.
  • This work highlights how the 3D I/O Pro™ workflow can characterize tumors based on complex spatial relationships within the tumor microenvironment, and could have broad applicability in research and development of novel cancer therapies that target tumor fibrosis or other features of the TME.

Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements at AACR 2024 with the Potential to Transform Cancer Diagnostics and Treatments

Retrieved on: 
Friday, April 5, 2024
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Artificial Intelligence, Genetics, Science, Diagnosis, Lung cancer, Algorithm, Immunotherapy, Patient, 2.0, University of Queensland, Biomarker, Tumor microenvironment, Marie Cassidy, Cancer, University, AI, Doctor of Philosophy, Medicine, AACR, Neoplasm, Drug development, Pathology, Therapy, Translational medicine, H&E, Medical imaging

Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.

Key Points: 
  • Nucleai's posters will highlight novel AI spatial biomarkers and enhanced histopathology workflows that promise to revolutionize cancer treatment and diagnostics.
  • Leveraging Nucleai's unique AI spatial biology solution, the research uncovered the correlation between the metabolic state and spatial distribution of tumor and immune cells in the tumor microenvironment, shedding new light on treatment outcomes and potential resistance mechanisms.
  • Nucleai is driving innovation in cancer research and collaborating with leading scientists to translate these findings into tangible benefits for patients and healthcare providers worldwide.
  • By integrating spatial biology with AI, Nucleai creates actionable insights from complex pathology data, setting a new standard for diagnosis and treatment, and advancing precision medicine.

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Inflammation, Harvard Medical School, DSP, Development, Gene expression, Immunotherapy, IL-6, Triple-negative breast cancer, RNA, King's College London, Immunology, Tumor microenvironment, Cancer, University, NanoString Technologies, Senior, Biology, Abstract, Pancreatic cancer, Neoplasm, Research and development, Hospital, Cell, SMI, MD Anderson Cancer Center, Blind spot, Medical imaging

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.

Key Points: 
  • NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.
  • The conference will be held in San Diego, April 5-10, 2024.
  • NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms.
  • “NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today.

Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline

Retrieved on: 
Wednesday, April 3, 2024
Research, Venture Capital, Professional Services, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, TME, IL18BP, Patient, Neoplasm, Tumor microenvironment, Biology, Biophysics, Therapy, Cancer, Structural biology, Escape Room

Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.

Key Points: 
  • Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors.
  • The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
  • Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways.
  • Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.

Merck’s Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment

Retrieved on: 
Wednesday, April 3, 2024
Research, Technology, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Biopsy, Algorithm, Entrepreneurship, Intelligence, Patient, Tumor microenvironment, Merck, Marie Cassidy, Cancer, AI, Spacecraft, Merck Group, Investment, Clinical trial, Drug development, Pathology, Therapy, Machine learning, Section 32, Spatial analysis, Medicine, Medical imaging

By integrating AI algorithms for prospective patient enrollment in clinical trials, Nucleai is spearheading a first-in-field approach to personalized medicine.

Key Points: 
  • By integrating AI algorithms for prospective patient enrollment in clinical trials, Nucleai is spearheading a first-in-field approach to personalized medicine.
  • Nucleai's platform tailors therapy strategies to the intricate cellular landscape of each patient, optimizing clinical trial participant selection.
  • Leveraging AI and machine learning (ML), Nucleai analyzes pathology images and spatial data at the cellular and tissue levels.
  • This innovation marks a shift in disease diagnosis and treatment, offering an in-depth contextual view that underpins the development of novel therapeutics.

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Retrieved on: 
Tuesday, April 2, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Development, Carcinoma, Drug discovery, Patient, Neoplasm, Tumor microenvironment, CT155, DLL3, AACR, Immunity, HKEX, ADC, SCLC, Pharmaceutical industry

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.

Key Points: 
  • Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California.
  • The global oncology programs to be showcased at AACR 2024 include a Phase 1a/1b study of ZL-1310 ( NCT06179069 ), a novel antibody-drug conjugate (ADC) within the Zai Lab pipeline that targets the Delta-like ligand 3 (DLL3), a validated therapeutic target for the treatment of small cell lung cancer (SCLC).
  • ZL-1310 is designed with a novel linker-payload platform TMALIN® which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies.
  • “These ongoing global clinical studies underscore Zai Lab’s continued commitment to pursue both novel and validated cancer biology targets and advance innovative oncology therapies that can potentially reach patients around the world,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, Zai Lab.

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Retrieved on: 
Thursday, March 28, 2024
Oncology, Health, Hospitals, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Therapeutic index, EPS, Patient, Gilead Sciences, Pharming, Tumor microenvironment, Science, Doctor of Philosophy, MD, Senior, IPR, Investment, Therapy, Cancer, Antibody, Cytokine, IL-12, Multimedia, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301.
  • View the full release here: https://www.businesswire.com/news/home/20240328734624/en/
    Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies.
  • Xilio will receive $43.5 million in upfront payments, including a cash payment of $30 million and an initial equity investment by Gilead of $13.5 million in Xilio common stock at a premium.
  • Xilio will be responsible for conducting clinical development of XTX301 in the ongoing Phase 1 clinical trial through dose expansion.

BostonGene Recognized as Designated Laboratory for the ComboMATCH Precision Medicine Clinical Trial

Retrieved on: 
Tuesday, March 26, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Health, Pharmaceutical, Artificial Intelligence, Oncology, NCI, Combination, Gene, ECOG, Physician, Patient, Malignancy, NGS, Biomarker, Research, DNA, RNA, Tumor microenvironment, National Cancer Institute, WES, Cancer, MD, Medicine, Microsatellite instability, Clinical trial, RNA-Seq, Bangladesh Technical Education Board, Drug resistance

BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.

Key Points: 
  • BostonGene , a leading provider of AI-driven, molecular and immune profiling solutions, today announced its participation in the Molecular Analysis for Combination Therapy Choice (ComboMATCH) precision medicine initiative as a designated laboratory.
  • ComboMATCH is a follow-up to the largest precision medicine clinical trial, the National Cancer Institute (NCI)-MATCH trial.
  • Already a CAP-accredited and CLIA-certified lab, BostonGene will now serve as a designated NGS laboratory for ComboMATCH.
  • “Our participation in the ComboMATCH trials underscores our commitment to advancing precision cancer medicine,” says Nathan Fowler, MD, Chief Medical Officer at BostonGene.

NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, NEO, Patient, Tumor microenvironment, Cancer, Abstract, AACR, Clinical trial, Annual general meeting, Medical imaging

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through innovative research and development initiatives.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, alongside research collaborators, will present key findings from 11 abstracts at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5-10 (booth #915), demonstrating its commitment to advancing cancer patient care through innovative research and development initiatives.
  • The breadth of data highlights NeoGenomics’ comprehensive approach to addressing various aspects of cancer diagnosis, treatment, and management.
  • “Our presence at the AACR 2024 Annual Meeting reflects our dedication and investment in advancing the field of precision oncology through groundbreaking research and collaborative partnerships," said Chris Smith, CEO of NeoGenomics.
  • By leveraging genomic and molecular analysis, NeoGenomics empowers healthcare providers with actionable insights to tailor treatment strategies and enhance patient outcomes.

Domain Therapeutics to Present Latest Data on DT-9045, a First-in-class Negative Allosteric Modulator of PAR2 for Immuno-oncology, at AACR 2024 Annual Meeting, Highlighting Clear Competitive Advantages of This Candidate

Retrieved on: 
Tuesday, March 26, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, GPCR, Gene, Immunotherapy, Patient, Immunosuppression, PAR2, ICB, Research, Tumor microenvironment, Cancer, G protein-coupled receptor, IND, AACR, Gq alpha subunit, Therapy, Drug resistance, Module (mathematics)

PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.

Key Points: 
  • PAR2 is one of the genes most significantly linked to resistance against immune checkpoint blockage (ICB) and T cells dysfunction in cancer patients.
  • Its upregulation across a variety of cancer types and expression on diverse cells within the tumor microenvironment underscore PAR2’s critical role in cancer development.
  • Remarkably, when compared to its most advanced competitors positioned in other therapeutic areas, this candidate has demonstrated clear differentiated features.
  • Stephan Schann, Chief Scientific Officer of Domain Therapeutics, commented: “We are excited to present our newest findings on DT-9045 at AACR.